Somewhat unusually, it said it would also like to see "more information from the company about the comparison between pembrolizumab plus chemotherapy with atezolizumab plus chemotherapy." ...

For those receiving pembrolizumab, the therapy was initiated at 2-6 weeks ... with all also receiving the immune checkpoint ...

NUC-3373 plus pembrolizumab in patients with advanced solid tumors 72-year-old patient with urothelial bladder cancer (Lynch syndrome) who had previously received gemcitabine plus cisplatin followed ...

In the adjuvant space, Leal highlighted IMpower010 (NCT02486718; atezolizumab) and KEYNOTE-091 (NCT02504372; pembrolizumab). Collectively, these therapies have substantially expanded the treatment ...

Exelixis, Inc. EXEL reported better-than-expected third-quarter results. Its shares have risen following the announcement.

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought. Though the 27 drugs ...

Exelixis’s Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. Read my EXEL ...

Current therapeutic options for SCLC include Merck & Co’s Keytruda (pembrolizumab), Bristol ... Imfinzi (durvalumab), and ...

Read more about A trial of chemoradiotherapy, pembrolizumab, and olaparib for small cell lung ... A trial of lurbinectedin and atezolizumab to improve treatment for small cell lung cancer (IMforte) ...

zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a phase 3 pivotal trial for the treatment of patients with head and neck squamous cell car NetraMark Holdings Inc. (the ...

Module 1 Selected Case Studies: NUC-3373 plus pembrolizumab in patients with advanced solid tumors: 72-year-old patient with urothelial bladder cancer who had previously received gemcitabine plus ...